Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
A Letter from Bob Hariri
Celularity Inc. Announces $3 Million Registered Direct Offering
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications
Celularity Human Placental-derived Advanced Biomaterials Demonstrate Superior Biocompatibility And Better Support Differentiated Cell Functions In Studies
Celularity Announces Presentation At Upcoming 7th International Conference On Orthopedics
Celularity Tissue Factor Gene Knockout Of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance Of Gene Editing Capability
Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement for Celularity’s Halal-certified Biomaterial Products
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation
A Letter from Bob Hariri
Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders For Celularity Branded Halal-Certified Biomaterial Products
Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy
Celularity Announces Clinical Data on Human Placental-derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate CYNK-001 in Adult Patients with Relapsed Refractory and Measurable Residual Disease-positive Acute Myeloid Leukemia
Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”
Celularity Inc. Announces $6 Million Registered Direct Offering
Celularity Announces Acceptance of Poster Presentation at 2023 Society For Biomaterials Annual Meeting
Celularity Receives U.S. Food and Drug Administration (FDA) Preliminary Assessment For Celularity's Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA's Center For Devices And Radiological Health
Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt
Letter from Bob Hariri
Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction For Its Investigational Celularity Tendon Wrap (CTW) To Be Regulated As A Device Within U.S. Food and Drug Administration (FDA) Center For Devices and Radiological Health (CDRH)
Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-up and Pipeline Prioritization of Next-Generation Product Candidates
Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia
Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East
Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies
Celularity Appoints Paul Graves as Chief Communications Officer
Celularity Stockholder Letter About Our Work in Osteoarthritis (OA)
Celularity Announces Halal Certification of its Advanced Cellular Therapeutics, Biomaterial Products and Business Model
VIEW PRESS RELEASES BY YEAR
THE LATEST COMPANY UPDATES & PRESS RELEASES
Celularity, Inc. (Nasdaq: CELU) headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron
Letter to shareholders
Celularity Inc. Announces $3 Million Registered Direct Offering
Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3L Ocular for Ophthalmic Applications
Celularity Human Placental-derived Advanced Biomaterials Demonstrate Superior Biocompatibility And Better Support Differentiated Cell Functions In Studies
Celularity Announces Presentation At Upcoming 7th International Conference On Orthopedics
Celularity Tissue Factor Gene Knockout Of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance Of Gene Editing Capability
Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement for Celularity’s Halal-certified Biomaterial Products
Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation